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Abstract
Dengue virus (DENV) is the most common arthropod-borne viral disease of humans. Although 
effective vaccines exist against other flaviviral diseases like yellow fever and Japanese 
encephalitis, dengue vaccine development is complicated by the presence of four virus serotypes 
and the possibility of partial immunity enhancing dengue disease severity. Several live attenuated 
dengue vaccines are being tested in human clinical trials. Initial results are mixed, with variable 
efficacy depending on DENV serotype and previous DENV exposure. Here, we highlight recent 
discoveries about the human antibody response to DENV and propose guidelines for advancing 
development of safe and effective dengue vaccines.
Hundreds of millions of people are infected annually by the four serotypes of dengue virus 
(DENV1–4), the etiological agents of dengue hemorrhagic fever/dengue shock syndrome 
(DHF/DSS) (Bhatt et al. 2013). Natural infection induces strongly neutralizing antibodies 
and lasting protective immunity to the homologous serotype. As highly effective live 
attenuated vaccines (LAVs) have been developed against other flaviviruses such as yellow 
fever and Japanese encephalitis viruses, the prospects for a dengue vaccine should be good 
(Murphy and Whitehead 2011). However, development of dengue vaccines is complicated 
by the presence of four distinct serotypes and the possibility of vaccine-enhanced severe 
dengue disease. Recently, several tetravalent dengue LAVs have been tested in human 
clinical trials with mixed results that highlight both the promise and problems of dengue 
vaccines (Rodriguez-Barraquer et al. 2014). Here, we review new information on the 
structural biology and immunology of DENVs and recent data from human natural infection 
and vaccination studies to identify best strategies for advancing dengue vaccines. Although 
antibodies and T cells both play important roles in DENV pathogenesis and protective 
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immunity, our discussion here pertains to B-cell and antibody responses. Additionally, 
although alternative approaches to dengue vaccines exist (e.g., inactivated, subunit, vectored, 
DNA), we focus this discussion on LAVs.
DENVs ARE HETEROGENEOUS AND DYNAMIC: IMPLICATIONS FOR 
VACCINE RESEARCH
The four DENV serotypes each independently crossed into humans several hundred years 
ago from sylvatic ancestors (Vasilakis et al. 2011). After adapting to the human transmission 
cycle, each serotype further diverged into different genotypes with distinct geographical 
distributions (Holmes and Twiddy 2003). Many DENV strains commonly used for research 
and vaccine development are strains that are no longer in circulation and/or have been 
heavily passaged in laboratories. The interactions of some human antibodies with DENVs 
can be profoundly influenced by genotype or passage history (Wahala et al. 2010; 
Sukupolvi-Petty et al. 2013). For example, the envelope (E) protein from DENV1 strain 
16007 (isolated in Thailand in 1964) is currently included as a vaccine antigen. DENV1 
16007 belongs to an extinct genotype and has mutations most likely derived from cell 
culture passage, which substantially alter neutralization sensitivity (Dowd et al. 2015). In a 
recent antigenic cartography study, this strain did not group with other DENV1 strains, 
further demonstrating its atypical properties (Katzelnick et al. 2015). Moving forward, we 
need to select the best representative contemporary strains for vaccine development and 
systematically assess whether vaccine-induced responses cover most major currently 
circulating strains.
The flavivirus virion contains two integral membrane proteins: E and premembrane/
membrane (prM/M). During virus secretion from infected cells, prM is cleaved to generate 
mature infectious virions, which have a smooth surface of E protein dimers. In cell lines 
commonly used to propagate DENVs or dengue LAVs, prM processing is inefficient and 
variable, and virions released from cells are a heterogenous mixture of immature, partially 
mature, and fully mature virions containing variable amounts of unprocessed prM (Plevka et 
al. 2014). The maturation state of DENV alters the specific infectivity of the virus to 
different cell lines (Rodenhuis-Zybert et al. 2010) and the ability of antibodies to bind and 
neutralize the virus (Pierson and Diamond 2012). In partially immature virions, the highly 
conserved fusion peptide on E is exposed, resulting in increased binding and neutralization 
by abundant cross-reactive antibodies in immune sera. Currently, maturation state is not 
monitored and controlled in dengue vaccine research.
The surface of the flavivirus virion contains 90 antiparallel E dimers that are tightly packed 
to form a protein coat with icosahedral symmetry. Recent studies have established that, in 
some DENV strains, the protein envelope is flexible and antibodies are able to bind to 
cryptic epitopes and neutralize the virus (Lok et al. 2008). This phenomenon, termed virus 
breathing, is influenced by temperature, time of incubation, and DENV strain, and specific E 
protein mutations can have profound effects on virus breathing and exposure of antibody 
epitopes (Kuhn et al. 2015). No systematic studies have been conducted to assess how the 
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extent of breathing varies according to serotype, genotype, strain, laboratory adaptation, and 
attenuation.
In summary, we now know that DENV serotypes are not monolithic. Rather, prM and E 
sequence variation, maturation state, and virus breathing have strong effects on epitope 
presentation and interactions with human antibodies. Most importantly, although we can 
account for serotype and genotype differences, we still do not know the maturation state and 
breathing/ flexibility of virions in people. Moving forward, basic and applied research on 
dengue vaccines has to be guided by existing information about the potential heterogeneity 
of DENV virions. We urgently need to define structural and biochemical properties of 
DENVs that circulate in humans.
LESSONS LEARNED FROM NATURAL DENV INFECTION STUDIES
Just as DENVs are not monolithic, the human immune response to DENV is variable, 
depending on serotype, strain, and the individual’s prior flavivirus infection history. DENVs 
have antibody epitopes that are conserved or variable among serotypes. People exposed to 
their first DENV infection (primary infection) develop memory B cells (MBCs) and long-
lived plasma cells (LLPCs) that produce antibodies that are cross-reactive or specific to the 
serotype of infection. Although cross-reactive antibodies are more abundant than type-
specific antibodies in serum and MBCs, the potently neutralizing antibodies are mainly 
directed to the serotype of infection (de Alwis et al. 2012, 2014). After a primary infection, 
an individual is reliably protected against disease caused by the homologous serotype only.
We have also learned that a person experiencing a secondary DENV infection with a new 
serotype develops a neutralizing and protective antibody response that is fundamentally 
different from a primary infection-induced response (Fig. 1). Secondary infections induce 
high levels of serotype cross-reactive antibodies that are, most likely, derived from MBCs 
from the first infection. These cross-reactive antibodies broadly neutralize two or more 
DENV serotypes, including serotypes not yet encountered (Corbett et al. 2015). Human 
cohort studies in dengue-endemic countries have also established that tertiary infections are 
nearly always mild or inapparent, implicating a protective role for broadly cross-neutralizing 
antibodies that develop after a second DENV infection (Olkowski et al. 2013).
The mere presence of anti-DENV antibodies is not sufficient for neutralization and 
protection. Importantly, not all neutralizing antibodies are protective to the same degree; 
thus, “quality” as well as “quantity” of anti-DENV neutralizing antibodies is paramount. As 
we discuss next, recent studies with human monoclonal antibodies (MAbs) derived from 
people exposed to primary or repeat infections have led to breakthroughs about the 
properties responsible for neutralization and protection.
Neutralizing and Protective Antibodies Induced after Primary DENV Infection
Serotype-specific human MAbs that strongly neutralize each serotype have been isolated 
from MBCs from people exposed to primary DENV infection (Beltramello et al. 2010; de 
Alwis et al. 2012). These antibodies bind to tertiary and quaternary structure epitopes on E 
present on intact virions or E homodimers (EDEs) but rarely on monomeric E protein (Fig. 
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2). These antibodies are protective in mouse models of DENV infection and disease, 
supporting a role for protective immunity in people (Teoh et al. 2012; Fibriansah et al. 
2015). Investigators have used recombinant DENVs to determine whether epitopes 
recognized by these MAbs are also targets of the polyclonal-type-specific serum neutralizing 
antibody response. For example, the DENV2-specific human MAb 2D22 binds to a 
quaternary epitope that includes critical residues on E domain III (EDIII) of DENV2. The 
2D22 epitope was successfully transplanted into DENV4 by creating a viable recombinant 
virus containing EDI and EDII from DENV4 and EDIII from DENV2 (Gallichotte et al. 
2015). Primary DENV2-immune sera efficiently neutralized the recombinant virus but not 
DENV4, demonstrating that the 2D22 epitope, and possibly other DENV2 epitopes in EDIII 
on the recombinant virus, are major targets of the human polyclonal neutralizing antibody 
response. A similar picture is emerging from studies with recombinant viruses displaying 
DENV1-, DENV3-, and DENV4-type-specific quaternary epitopes (AM de Silva and RS 
Baric, unpubl.). We propose that quaternary epitopes that are unique to each serotype are the 
main targets of neutralizing and protective antibodies induced after primary DENV 
infection. Studies are ongoing to define how the primary neutralizing antibody response 
directed to these epitopes evolves over time and how the response varies depending on virus 
strain and individual infected.
Neutralizing and Protective Antibodies Induced after Secondary DENV Infection
Secondary DENV infections induce durable cross-neutralizing antibodies and cross-
protective immunity. Several cross-neutralizing human MAbs, which bind to an epitope near 
the bcloop on domain II of the E protein monomer, have been described (Smith et al. 2013; 
Tsai et al. 2013; Dejnirattisai et al. 2015). A novel class of serotype cross-reactive and 
strongly cross-neutralizing MAbs, which bind to quaternary epitopes on the E homodimer 
(EDE), was recently isolated from plasmablasts collected a few days after recovery from an 
acute secondary DENV infection (Dejnirattisai et al. 2015; Rouvinski et al. 2015). Other 
groups have also isolated plasmablasts from acute secondary dengue cases and mainly 
observed cross-reactive but weakly neutralizing antibodies (Fink 2012; Wrammert et al. 
2012). The methods used to screen plasmablasts, the timing of sample collection, and 
individual variation and DENV infection histories may account for these differences. 
Furthermore, it is unclear whether the strongly cross-neutralizing MAbs isolated from acute-
phase plasmablasts are maintained as MBCs and LLPCs. Several studies are currently in 
progress to define the origin and evolution of broadly neutralizing, cross-protective antibody 
responses. We propose that some low-affinity cross-reactive antibody-producing MBCs 
induced by primary infection are activated and affinity matured by repeat infections to 
generate higher-affinity cross-neutralizing antibodies such as the EDE antibodies. 
Development and evaluation of dengue vaccines must be grounded on the fundamentally 
different properties of neutralizing and protective antibodies that develop in naïve and 
partially immune individuals.
LESSONS LEARNED FROM DENGUE LAVs
LAVs have been successfully developed for several flaviviruses, and this approach holds 
much promise for a dengue vaccine. Because of the possibility of a monovalent vaccine 
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inducing cross-reactive immunity that enhances replication and disease caused by other 
DENV serotypes, all leading dengue vaccines are based on tetravalent formulations to 
induce simultaneous protective responses to all four serotypes. Three dengue LAVs, based 
on recombinant attenuated DENV serotypes (NIH) or recombinant yellow fever virus 
(Sanofi) or DENV2 (Takeda) constructs expressing the prM and E genes from the four 
serotypes (Murphy and Whitehead 2011), are currently at different stages of evaluation in 
phase 3 or 4 clinical trials. The leading candidate, Dengvaxia, developed by Sanofi Pasteur, 
has been approved for use in individuals above the age of 9 years in several countries (Guy 
and Jackson 2015). The first hurdle faced by developers was balanced replication of the four 
viruses in the tetravalent vaccine. Although all vaccines induced neutralizing antibodies to 
all four serotypes, some components have replicated better than others, and a strong positive 
correlation has been observed between vaccine virus replication and the magnitude and 
quality of neutralizing antibodies.
Efficacy Data from Dengvaxia
Currently, vaccine efficacy data is only available for Dengvaxia, which reduced the number 
of laboratory-confirmed cases of dengue disease in Asia and Latin America (Hadinegoro et 
al. 2015). However, vaccine efficacy varied by serotype, with higher efficacy rates against 
DENV3 and -4 than against DENV1 and -2 (Hadinegoro et al. 2015). The DENV3 and -4 
components in the vaccine replicated better than the DENV1 and -2 components in 
preclinical animal studies and phase 1 human studies, establishing a correlation between 
vaccine virus replication and efficacy. Importantly, Dengvaxia efficacy was higher in 
participants with prior exposure to DENV than in participants dengue-naïve at baseline, 
demonstrating that it is easier to induce protective responses in DENV-primed individuals 
compared with naïve subjects (Hadinegoro et al. 2015). We have gained the following 
insights from this first dengue vaccine efficacy trial. First, just the presence of in vitro 
neutralizing antibodies is not sufficient for protection because many individuals experienced 
breakthrough infections despite having neutralizing antibodies to the breakthrough serotype. 
Second, the vaccine performed very differently in DENV-naïve versus-primed individuals, 
establishing the profound impact of immunological memory on vaccine performance.
A CONTEMPORARY FRAMEWORK FOR DENGUE VACCINE 
DEVELOPMENT
Moving forward, we strongly recommend separating the evaluation of vaccine performance 
in DENV-naïve and -primed individuals, as the barriers to inducing protective immunity and 
the specific properties of neutralizing/protective antibodies are fundamentally different in 
these two populations (Fig. 3). All dengue vaccine trials must be designed to obtain separate 
safety and efficacy data for these two populations because it is not possible to extrapolate 
results from one group to the other (Rodriguez-Barraquer et al. 2015;Russell and Halstead 
2016).
Effective Vaccination of DENV-Naïve Individuals
The population with the greatest need for a dengue vaccine is young children living in 
endemic countries. The majority of children will be DENV-naïve at vaccination. What are 
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the likely properties of vaccine-induced protective antibodies in this population? In people 
exposed to primary DENV infections, the neutralizing and protective antibody response is 
dominated by type-specific antibodies; thus, cross-reactive neutralizing antibodies induced 
by unbalanced and robust replication of one or two serotypes in a tetravalent vaccine are 
unlikely to provide durable protection against all four serotypes in this naïve population. In 
fact, DENV-naïve subjects who received Dengvaxia developed high levels of type-specific 
neutralizing antibodies to DENV4, whereas the DENV1, -2, and -3 responses were 
dominated by cross-reactive neutralizing antibodies (Henein et al. 2017), possibly derived 
from the DENV4 component that replicated the best in vaccinees. We propose that balanced 
replication leading to type-specific antibodies that target quaternary epitopes in each 
serotype is the key to effective vaccination of naïve individuals.
Effective Vaccination of DENV-Primed Individuals
Secondary DENV infections result in activation of MBCs and development and expansion of 
cross-reactive antibodies that broadly neutralize multiple DENV serotypes, driven by the 
sequential infection and robust replication of two different serotypes of DENV. We propose 
that a similar mechanism is responsible for the superior performance of tetravalent LAVs in 
DENV-primed individuals. In a subject with preexisting DENV-specific MBCs, even 
unbalanced replication of one or two vaccine components is likely to activate MBCs and 
expand somatically mutated higher-affinity cross-reactive clones with capacity to broadly 
neutralize multiple serotypes.
HOW SAFE ARE DENGUE VACCINES?
A major concern regarding dengue vaccines is the potential for increased risk of enhanced 
disease in vaccine recipients who mount an insufficient/suboptimal immune response or 
after initially protective levels of antibodies wane to potentially enhancing levels. These 
concerns are based on epidemiological studies that have shown that a second infection with 
a new serotype or natural infection of 6- to 12-month-old infants of DENV-immune mothers 
leads to increased risk of severe disease (Burke et al. 1988; Kliks et al. 1988). This 
phenomenon is posited to be a result, in part, of antibody-dependent enhancement (ADE), 
whereby nonneutralizing antibodies to a previous DENV infection bind to the new serotype 
and facilitate its entry into target Fcγ receptor (FcγR)-bearing cells, leading to higher 
viremia and immune activation (Halstead 1988). However, studies of ADE in human 
populations remain controversial. Some studies have shown that sera from children who 
develop more severe disease are more enhancing in vitro (Kliks et al. 1988; Chau et al. 
2008); other studies have not found this to be the case (Laoprasopwattana et al. 2005; 
Libraty et al. 2009). Certainly, serotype cross-reactive antibodies (and even serotype-specific 
antibodies at high enough dilution) can cause ADE in vitro in numerous FcγR-bearing cells; 
the issue remains whether in vitro results can be extrapolated to human studies and, 
currently, we do not have robust serological assays for accurately predicting risk of ADE and 
severe disease in people. The most convincing evidence for ADE has come from animal 
studies. Prior administration of subneutralizing levels of polyclonal serum or MAbs can 
enhance DENV replication in nonhuman primates (Goncalvez et al. 2007) and cause a lethal 
vascular leak syndrome in mouse models (Balsitis et al. 2010; Zellweger et al. 2010). 
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Further studies with mice passively administered human DENV immune sera showed that 
DENV cross-reactive antibodies that bound to recombinant E and prM proteins were 
responsible for ADE in the lethal mouse model (de Alwis et al. 2014). However, it is still 
unclear exactly how such animal studies translate into severe disease in humans, although a 
new study demonstrates that a specific range of low-titer antibodies predicts risk of severe 
dengue disease in a pediatric cohort study in Nicaragua (L Katzelnick and E Harris, 
unpubl.).
The most direct evidence about vaccine safety emerges from the clinical trials themselves. 
During the long-term follow-up period of the Sanofi phase 3 trial in Asia, children who 
received the vaccine had an increased risk of hospitalization because of dengue compared 
with the placebo group (Hadinegoro et al. 2015). As children were more likely to be DENV-
naïve compared with adults at the time of vaccination, the most parsimonious explanation 
for this safety signal is that vaccination of naïve individuals predisposed them to more severe 
disease. The increased risk of hospitalization peaked in the second year after vaccination, 
demonstrating that immunity to flaviviruses and potential susceptibility to ADE is a 
“moving target” as the immune response wanes. It is also possible that other factors such as 
age and “temporal clustering” of cases are responsible for the increased number of 
hospitalized cases (Guy and Jackson 2015). The entire dengue vaccine community will learn 
a great deal from the intense studies currently in progress to better understand the overall 
efficacy patterns and safety profile of Dengvaxia (Guy and Jackson 2015).
FUTURE DIRECTIONS
Immune correlates of protection and vaccine efficacy are urgently needed. Several recent 
studies confirm that neutralizing antibody titer is associated with protection from 
symptomatic disease (Endy et al. 2004; Katzelnick et al. 2016); improved correlates will 
emerge as epitope-specific diagnostics become available. However, it seems likely that 
particular immune correlates will be specific for each DENV serotype and vaccine; it is also 
possible that the threshold of neutralizing antibodies or other immune correlates that protect 
against subsequent infection is also influenced by the force of infection of a given epidemic 
(Katzelnick et al. 2016). Furthermore, it must be kept in mind that neutralization titers vary 
substantially across laboratories and between methods, with numerous assay parameters 
significantly affecting the outcome (Thomas et al. 2009), adding yet another layer of 
complexity.
Another discussion has been whether a vaccine containing fewer than four serotypes could 
be safe and efficacious. This would depend on generating effective protective cross-reactive 
responses, and, until we know how to elicit such responses in all vaccinees, it is critical to 
include LAV or immunogens from all four serotypes. Another approach under development 
is bivalent vaccine candidates, wherein key neutralizing epitopes from one serotype are 
transplanted to another serotype while maintaining protective epitopes in the recipient virus 
(Gallichotte et al. 2015; Messer et al. 2016). In this case, the determining factor is the 
universality of the particular epitope(s) in question. Finally, a strategy under active 
investigation by several groups is the construction of scaffolded vaccines, whereby only the 
epitope(s) of interest is displayed in the proper configuration on a neutral scaffold or, 
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alternatively, development of methods to mask epitopes that may generate “unwanted” 
nonneutralizing/nonprotective antibodies. These latter approaches have been shown with 
other targets, such as HIV or respiratory syncytial virus (RSV) (McLellan et al. 2011); the 
challenge is to apply these methods to solve the dengue vaccine conundrum.
CONCLUSIONS
The development of the dengue LAVs currently in clinical trials started several decades ago. 
In the interim, we have learned a lot about the structural properties of DENVs and the 
human antibody response to natural infections. We will gain unprecedented insight into how 
dengue LAVs can be safe and effective from the current clinical trials. Although we 
acknowledge the difficulty of the long timeline from initial formulation of vaccine to clinical 
trials, in this review we have provided a framework for incorporating new information about 
DENVs and the human antibody response to these viruses to advance the development of 
dengue vaccines.
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What are the most interesting topics likely to come up over dinner or drinks with your 
colleagues? Or, more importantly, what are the topics that don’t come up because they 
are a little too controversial? In Immune Memory and Vaccines: Great Debates, Editors 
Rafi Ahmed and Shane Crotty have put together a collection of articles on such 
questions, written by thought leaders in these fields, with the freedom to talk about the 
issues as they see fit. This short, innovative format aims to bring a fresh perspective by 
encouraging authors to be opinionated, focus on what is most interesting and current, and 
avoid restating introductory material covered in many other reviews.
The Editors posed 13 interesting questions critical for our understanding of vaccines and 
immune memory to a broad group of experts in the field. In each case, several different 
perspectives are provided. Note that while each author knew that there were additional 
scientists addressing the same question, they did not know who these authors were, which 
ensured the independence of the opinions and perspectives expressed in each article. Our 
hope is that readers enjoy these articles and that they trigger many more conversations on 
these important topics.
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Neutralizing antibody response after a first versus a second natural dengue virus (DENV) 
infection. Shown are representative neutralization curves from a first (A,B) versus a second 
(C,D) DENV infection from children in a dengue cohort study in Nicaragua (Katzelnick et 
al. 2016). The preinfection (A,C) and postinfection (B,D) (>6 months postinfection) 
neutralizing antibody responses are depicted, demonstrating a fundamentally different 
response in primary (i.e., first) versus second DENV infection. A table with the 50% 
neutralization titers (NT50) is included below each set of graphs. Data were derived from 
neutralization assay performed in U937 human monocytic cells expressing the DENV 
attachment factor DC-SIGN and reporter viral particles representing DENV1, -2, -3, and -4 
as described in Montoya et al. (2013).
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Location of quaternary epitopes recognized by serotype-specific human monoclonal 
antibodies (MAbs) that neutralize dengue viruses (DENVs). The DENV E protein has three 
domains, designated E domain I (EDI, red), E domain II (EDII, yellow), and E domain III 
(EDIII, blue). The viral fusion loop at the tip of EDII is indicated in green. E protein is 
present as a homodimer that lies flat on the surface of the mature virion. The white box 
depicts a raft of three E protein homodimers, which is the basic building block of the 
flavivirus envelope. Thirty rafts tightly pack to form a protein envelope with icosahedral 
symmetry. The approximate footprints of DENV1-specific (1F4 and 14C10), DENV2-
specific (2D22), and DENV3-specific (5J7) human MAbs are circled. Note that the DENV1 
MAb footprint encompasses EDI/II and EDIII from adjacent dimers. The DENV2 MAb 
footprint spans EDII and EDIII within a homodimer. The DENV3 MAb footprint includes 
contact residues from EDI, EDII, and EDIII of three different E protein subunits. (Adapted 
from www.purdue.edu/uns/images/kuhn.dengue1.jpeg.)
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Effect of preexisting dengue virus (DENV) immunity on antibody responses to balanced and 
unbalanced tetravalent live attenuated (TV-LAV) vaccines. (A) Levels of neutralizing 
antibodies after first and second natural DENV infections with different serotypes. After the 
first infection, there is a rapid increase in neutralizing antibodies to all four serotypes, which 
decline over time. Type-specific antibodies to the homologous serotype (blue) are 
maintained at higher levels, whereas antibodies to heterologous serotypes decline and are 
maintained at lower levels or become undetectable. A second infection with a new serotype 
(green) leads to high levels of neutralizing antibodies to the four serotypes, which decline 
over time. Compared with the first infection, higher levels of DENV serotype cross-reactive 
neutralizing are maintained after a second infection. Neutralizing antibody responses in 
DENV-naïve subjects who received a balanced (B) or unbalanced (C) TV-LAV. Avaccine 
with balanced replication of all four serotypes (B) will induce durable, type-specific 
neutralizing antibody responses to the four serotypes. After vaccination with an unbalanced 
TV-LAV (C), dominant replication of one serotype will, initially, induce neutralizing 
antibodies to all four serotypes, which decline over time. Type-specific antibodies to the 
dominant serotype will be maintained, whereas antibodies to other serotypes will decline to 
low or undetectable levels. Neutralizing antibody responses in DENV preimmune subjects 
who received a balanced (D) or unbalanced (E) TV-LAV. A vaccine with balanced 
replication of all four serotypes (D) will induce durable, type-specific, and cross-reactive 
neutralizing antibody responses to the four serotypes. A vaccine with unbalanced, dominant 
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replication of one serotype (E) will be similar to a secondary natural secondary DENV 
infection. The unbalanced vaccine will induce variable levels of type-specific and cross-
reactive neutralizing antibodies to each of the four serotypes. The four colored lines 
represent evolving antibody responses to each of the four serotypes of DENV. The dashed 
black line represents a hypothetical neutralizing titer required for protection. In reality, the 
absolute titer for protection is likely to be different for each serotype and also influenced by 
the quality of neutralizing antibodies. Neut Ab, Neutralizing antibody.
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